Aeruginosin 865, a compound extracted from the terrestrial cyanobacterium Nostoc sp. Luke ová 30/93, represents the inaugural aeruginosin-type peptide to incorporate a fatty acid and a carbohydrate moiety. It functions by inhibiting the translocation of NF-kB to the nucleus, thereby exerting an anti-inflammatory effect.

Aeruginosin 865, when pre-treated at concentrations ranging from 0.1 to 100 μg/mL, significantly inhibits IL-8 (EC 50 = 3.5 μg/mL) and ICAM-1 (EC 50 = 50.0 μg/mL) in a concentration-dependent manner in hTNF-α-stimulated HLMVECs, without compromising cell viability in HeLa and HepG2 cells even at much higher concentrations[1]. Furthermore, at concentrations of 100-200 μM, Aeruginosin 865 exhibits cytotoxicity towards Mouse fibrosarcoma cells, while demonstrating no cytotoxic effects on NIH/3T3 cells[2].